Goldman Sachs upgraded Pro Medicus to Buy from Neutral with a price target of A$76, up from A$57.90. The firm expects the adoption of Pro Medicus’ technology to expand and its new estimates imply a 22% EBITDA compound annual growth rate from FY23-26.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PMCUF: